Neogenomics Inc (NEO) Stock Analysis
Verdict: WATCH (do not buy)
Operational turnaround and RaDaR Medicare expansion drive growth, but high valuation (EV/EBITDA 62x) and $448M debt cap near-term upside.
Investment score: 59/100
Analysis as of
Is Neogenomics Inc stock worth reviewing? The TradeMates thesis
The model rates NeoGenomics as a HOLD with an Investment Score of 59/100. Strong operational execution and clinical assay expansion support long-term upside, but full current valuations require patient entry timing on technical dips.
7-factor investment score
- Valuation: 35/100 (weight 20%)
- Financial Health: 55/100 (weight 15%)
- Technical Momentum: 75/100 (weight 15%)
- Earnings Quality: 85/100 (weight 15%)
- Insider Sentiment: 35/100 (weight 10%)
- Analyst Consensus: 75/100 (weight 10%)
- Risk-Adjusted Return: 55/100 (weight 15%)
Neogenomics Inc opportunities and risks
What speaks for NEO
- Medicare MolDX Reimbursement Coverage Expansion for RaDaR ST Assay
What speaks against NEO
- Extreme Valuation Multiples Leaves No Margin for Operational Error
Peers and competitors
| Ticker | P/E | P/S | EV/EBITDA | Gross margin | Net margin | FCF yield |
|---|---|---|---|---|---|---|
| NEO | n/a | 0.6x | 62.0x | 42.9% | -6.8% | -1.5% |
| OPCH | 17.3x | 0.6x | 10.9x | 18.2% | 3.7% | 10.0% |
| AVAH | 9.3x | 1.0x | 13.7x | 32.0% | 10.6% | 6.1% |
| GRDN | 39.2x | 1.8x | 22.4x | 21.6% | 4.5% | 3.1% |
| PRVA | 87.6x | 1.1x | n/a | 7.6% | 1.2% | -1.9% |
| PINC | 59.4x | 0.0x | 1.5x | 73.0% | 9.4% | 710.2% |
| Peer median | 39.2x | 1.0x | 10.9x | 21.6% | 4.5% | 6.1% |
Frequently asked questions about Neogenomics Inc (NEO)
Is NEO stock a good investment?
The TradeMates model rates Neogenomics Inc as WATCH (do not buy) with an investment score of 59/100. The model rates NeoGenomics as a HOLD with an Investment Score of 59/100. Strong operational execution and clinical assay expansion support long-term upside, but full current valuations require patient entry timing on technical dips. This is algorithmic model output, not personal investment advice.
Is NEO stock a buy?
The TradeMates model verdict for NEO is WATCH (do not buy) with an investment score of 59/100. Treat this as a model signal to review, not a personal buy recommendation.